MedTrace Logo

Allergic Rhinitis Combination Pharmacotherapy Efficacy Study

NCT04601324 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2023-10-31

No results posted yet for this study

Summary

Combination pharmacotherapy is often used in people who have failed mono-therapies in managing their bothersome allergic rhinitis symptoms . However, there is a paucity of research indicating the most effective combination therapies in managing allergic rhinitis. This study aims to evaluate the efficacy of oral antihistamine (rupatadine) combined with nasal steroid (fluticasone propionate) compared to a well-studied combination therapy of nasal steroid with nasal antihistamine spray (MP-AzeFlu).

Conditions

  • Allergic Rhinitis

Interventions

DRUG

Fluticasone Propionate

Participants will be required to use fluticasone propionate nasal spray twice daily.

DRUG

Azelastine hydrochloride and fluticasone propionate

Participants will be required to administer twice daily MP-AzeFlu nasal spray (formulation of 137 mg of azelastine hydrochloride/50 mg of fluticasone propionate) separated by 12 hours.

DRUG

Rupatadine

Rupatadine once daily for a total of 2 weeks.

Sponsors & Collaborators

  • St. Paul's Sinus Centre

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
19 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2021-06-01
Completion
2021-07-01
FDA Drug
Yes

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04601324 on ClinicalTrials.gov